These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Tacrolimus (FK 506): an immunosuppression alternative in solid organ transplantation. (Part 2)]. Díaz M; Azanza JR; Sádaba B; López de Ocáriz A Rev Med Univ Navarra; 1995; 40(2):93-108. PubMed ID: 7569553 [No Abstract] [Full Text] [Related]
7. Comparison of the temporal profile of calcineurin inhibition by cyclosporine and tacrolimus in renal transplant patients. Koefoed-Nielsen PB; Karamperis N; Jørgensen KA Transplant Proc; 2005 May; 37(4):1736-8. PubMed ID: 15919449 [TBL] [Abstract][Full Text] [Related]
8. FK 506: a new immunosuppressive agent for organ transplantation. Pharmacology, mechanism of action and clinical applications. Fagiuoli S; Gasbarrini A; Azzarone A; Francavilla A; Van Thiel DH Ital J Gastroenterol; 1992; 24(6):355-60. PubMed ID: 1381245 [No Abstract] [Full Text] [Related]
9. [The anti-calcineurins (cyclosporin and tacrolimus)]. Raymond S; Limat S; Woronoff-Lemsi MC Soins; 2007 Jun; (716):61-3. PubMed ID: 17718044 [No Abstract] [Full Text] [Related]
10. Catatonia as a manifestation of tacrolimus-induced neurotoxicity in organ transplant patients: a case series. Chopra A; Das P; Rai A; Kuppuswamy PS; Li X; Huston J; Philbrick K; Sola C Gen Hosp Psychiatry; 2012; 34(2):209.e9-11. PubMed ID: 21937118 [TBL] [Abstract][Full Text] [Related]
11. CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation. Wang J Expert Rev Mol Diagn; 2009 May; 9(4):383-90. PubMed ID: 19435458 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the new EMIT tacrolimus assay in kidney and liver transplant recipients. Akbas SH; Yavuz A; Tuncer M; Yurdakonar E; Akcit F; Gurkan A; Demirbas A; Gultekin M; Ersoy F; Akaydin M Transplant Proc; 2004; 36(1):86-8. PubMed ID: 15013308 [TBL] [Abstract][Full Text] [Related]
13. Tacrolimus disposition in the ascitic fluid of a bone marrow transplant patient. Ibrahim RB; Abidi MH; Al-Kadhimi Z; Uberti JP; Edwards DJ Ann Pharmacother; 2010 May; 44(5):939-40. PubMed ID: 20371750 [No Abstract] [Full Text] [Related]
14. A risk-benefit assessment of tacrolimus in transplantation. Winkler M; Christians U Drug Saf; 1995 May; 12(5):348-57. PubMed ID: 7545405 [TBL] [Abstract][Full Text] [Related]
15. Overview of tacrolimus-based immunosuppression after heart or lung transplantation. Reichenspurner H J Heart Lung Transplant; 2005 Feb; 24(2):119-30. PubMed ID: 15701425 [TBL] [Abstract][Full Text] [Related]
16. The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy: recent developments. Oellerich M; Armstrong VW Ther Drug Monit; 2006 Dec; 28(6):720-5. PubMed ID: 17164686 [No Abstract] [Full Text] [Related]
18. Consideration of the ethnic prevalence of genotypes in the clinical use of tacrolimus. Andrews LM; De Winter BC; Van Gelder T; Hesselink DA Pharmacogenomics; 2016 Nov; 17(16):1737-1740. PubMed ID: 27790923 [No Abstract] [Full Text] [Related]
19. Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients. Billaud EM; Guillemain R; Tacco F; Chevalier P Br J Clin Pharmacol; 1998 Sep; 46(3):271-2. PubMed ID: 9764970 [No Abstract] [Full Text] [Related]
20. Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient. Barau C; Blouin P; Creput C; Taburet AM; Durrbach A; Furlan V Fundam Clin Pharmacol; 2009 Aug; 23(4):423-5. PubMed ID: 19709321 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]